Department of Rheumatology and Immunology, Peking University People's Hospital; Beijing Key Laboratory of Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases (Peking University People's Hospital), Beijing, 100044, China.
Auto-generated profile, based on publicly available information
Tian Liu
Department of Rheumatology and Immunology, Peking University People's Hospital; Beijing Key Laboratory of Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases (Peking University People's Hospital), Beijing, 100044, China.
Background: Autoimmune responses have been suggested to involvement in patients with Behcet’s syndrome (BS). There has been growing attention towards the roles of cutaneous lymphocyte antigen (CLA)+ regular T cells (Tregs) in autoimmune diseases. The role of CLA+ Tregs in BS is still uncertain. This study aims to clarify the impact of CLA+ Tregs on BS. Methods: We collected peripheral blood from a total of 107 patients with BS and 114 healthy controls (HCs). The number of CLA+ Tregs, natural killer (NK) cells, B cells, and several subtypes of CD4+ T cells were detected using flow cytometry and compared between patients and HCs. Results: The absolute number and proportion of CLA+ Tregs among CD4+ T lymphocytes and CD4+ Tregs were lower in patients with BS than in HCs. CLA+ Tregs were positively related with NK cells (r = 0.500, P < 0.001) and B cells (r = 0.470, P < 0.001) and negatively related with effector T cells (r=-0.402, P < 0.001) in patients with BS. Patients with BS and arterial aneurysms had CLA+ Treg cell deficiency. A decreased proportion of CLA+ Tregs was associated with arterial aneurysms in patients with BS. The proportion of CLA+ Tregs in patients with BS increased with corticosteroids and immunosuppressants. Conclusion: CLA+ Tregs decrease in association with arterial aneurysm in patients with BS. CLA+ Tregs may be a predictor of response to BS treatment.
Behçet’s syndrome (BS), a chronic vasculitis, leads to recurrent oral ulcers, severely impacting quality of life. Here we report the results of a randomized, double-blind, placebo-controlled trial (NCT04065672) to evaluate the efficacy and safety of low-dose interleukin-2 (LD-IL-2) in BS patients. 60 participants with active oral ulcers are randomly assigned to receive LD-IL-2 or placebo. The primary endpoint is the oral ulcer count at week 12. The LD-IL-2 group has significantly fewer oral ulcers than the placebo group (0.69 ± 1.05 vs. 1.57 ± 0.90, P = 0.001) with greater improvements in ulcer pain, disease activity, and quality of life. No infections or severe adverse events are observed in either group. LD-IL-2 expands regulatory T (Treg) cells and decreased the ratio of effector T cell to Treg cells. Thus, LD-IL-2 therapy might be an effective and safe treatment in BS patients and is associated with the modulation of CD4 + T cell populations.
This study aimed to evaluate the efficacy and safety of upadacitinib in patients with refractory Behcet’s syndrome (BS). A multicentre, single-arm trial was conducted from February 2023 to August 2025. Eligible patients had BS refractory to at least two immunosuppressive agents or one targeted therapy for a minimum of 6 months. Participants discontinued previous targeted therapies and received upadacitinib 15 mg/day for up to 48 weeks, in addition to their ongoing glucocorticoid and immunosuppressant regimens. Clinical features, inflammatory markers, imaging findings, and treatment data were collected throughout follow-up. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at 24 weeks. Twenty-seven patients (16 male; median age 36 years) were enrolled, with a median baseline BDCAF score of 4 (range: 2–7). Affected systems included the mucocutaneous, articular, gastrointestinal, cardiovascular, and ocular systems. The ORR at 24 weeks was 85.2% (23/27), comprising 16 CRs and 7 PRs. Significant reductions were observed in median BDCAF scores, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and glucocorticoid dosage by week 24. Among the 23 patients who achieved remission at week 24, median CRP and ESR levels at 48 weeks were significantly lower than those at 24 weeks. For clinical responses across different systems, CR was achieved in 3 (100.0%) with cardiovascular involvement, 5 (83.3%) with ocular symptoms, 10 (76.9%) with gastrointestinal involvement, 16 (59.3%) patients with mucocutaneous symptoms, and 1 (16.7%) with articular involvement at 24 weeks. Three patients experienced relapse during the follow-up. No serious adverse events were reported. Upadacitinib represents a potential therapeutic option for patients with refractory BS. The online version contains supplementary material available at 10.1186/s13075-026-03778-x.
28 August 2024 in Clinical and Experimental Medicine
Behcet's syndrome (BS) is a vasculitis characterized by immune dysregulation. Biomarkers are valuable for assessing clinically atypical pathogenesis. We aimed to investigate the distribution of different biomarkers and their effects on the clinical features of patients with BS in a large-scale, real-world study. This is a retrospective, single-center study. In total, 502 patients diagnosed with BS were enrolled in this study. We analyzed the clinical features of this cohort and divided patients’ symptoms into six categories, including mucocutaneous, articular, neurological, gastrointestinal, vascular, and ocular involvements. HLA-B51 cells, autoantibodies, and subsets of immune cells from the patients were tested. Pearson’s correlation, Wilcoxon rank sum test and multivariate logistic regression were used for data analysis. Various autoantibodies were detected in the serum of 40.8% of patients with BS. The positivity rate of anti-endothelial cell antibodies (AECA) was the highest among autoantibodies and was found in 23.5% (118/502) of patients with BS. The positivity rate of HLA-B51 in patients with BS was 27.1%. Tumor necrosis factor (TNF)-α, IL-2, and IL-4 producing CD4+ T cells were positively correlated with the gastrointestinal BS. Increased IL-4+CD4+ T cell was a risk factor for gastrointestinal BS (P = 0.006, Overall rate [OR] = 2.491, 95% Confidence interval [CI]: [1.317, 5.100]). Various autoantibodies can be detected in patients with BS. HLA-B51 and AECA are the most common biomarkers. Increased IL-4+ CD4+ T cell was a risk factor for gastrointestinal involvement in BS.
Objective: This study aimed to assess the efficacy and safety of baricitinib in Takayasu arteritis (TAK) refractory to TNF-α inhibitors. Methods: We conducted a multicentre, single-arm trial between February 2021 and August 2023. Patients with TAK unresponsive to at least 6 months of TNF-α inhibitors were treated with baricitinib 4 mg daily for up to 48 weeks, while continuing of immunosuppressants and glucocorticoids. Clinical features, inflammatory parameters, imaging changes and treatment data were collected during follow-up. The primary end point was the overall response (ORR) (complete response [CR] plus partial response [PR]) at 24 weeks. Results: A total of 10 patients (nine female and one male) patients were enrolled, with median age of 29 years (26.0, 35.3) and a median disease duration of 56.5 months (31.8, 88.5). The ORR at 24 weeks was 80%, with six patients achieving CR and two achieving PR. Disease progression was noted in the remaining two patients. Disease activity, ESR and CRP at 24 weeks were significantly decreased compared with those at baseline. The median glucocorticoid dosage decreased from 20.0 mg/day (15.0, 26.3) at baseline (P < 0.001) to 6.3 mg/day (4.4, 10.6) at 24 weeks. No relapse was observed in the eight patients who achieved a response. The adverse effects (AEs) included upper respiratory tract infection (n = 2) and diarrhoea (n = 1), with no serious AEs reported. Conclusion: Baricitinib is effective in patients with TAK resistant to conventional treatments and anti-TNF-α therapy and demonstrates a notable steroid-sparing effect. Trial registration: ClinicalTrials.gov; NCT06662721.